Why Brazil's public health system doesn't cover obesity medications

uol.com.br (Portuguese)

Brazil's public health system, SUS, does not offer obesity medications due to high costs. The National Health Technology Incorporation Commission (Conitec) recently denied inclusion of semaglutide and liraglutide, citing estimated annual costs of R$8 billion, nearly double the 2025 Popular Pharmacy budget. Medical societies criticize this decision, arguing it contradicts SUS principles and that medication for obesity is a long-term investment in public health, with costs expected to decrease over time.


With a significance score of 3.4, this news ranks in the top 9.4% of today's 30017 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: